PTC’s Ataluren and Accelerated Approval: Is Eteplirsen A Precedent After All?

US FDA appears willing to consider accelerated approval for PTC's Duchenne Muscular Dystrophy therapy ataluren if company is able to provide compelling evidence of increased levels of dystrophin in boys with nonsense-mutation DMD. That is quite a reversal from the agency’s view heading into PTC’s appeal. 

Grand Canyon
Precedent or Precipice? The US FDA might be headed into a beautiful landscape – or towards a steep, rocky cliff. • Source: Tony Hisgett

Is history repeating itself with another potential therapy to treat Duchenne Muscular Dystrophy?

A Feb. 20 press release from PTC Therapeutics Inc. about its appeal of the US FDA’s rejection of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approval Standards

More from Pathways & Standards